NCT03149055View on ClinicalTrials.gov

Fungal Prophylaxis With Isavuconazole for Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant (HCT)

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 4, 2017

Primary Completion Date

August 20, 2019

Study Completion Date

November 8, 2021

Conditions

Hematologic MalignancyMyeloproliferative Disorder

Interventions

DRUG

Isavuconazole

Intravenous or oral: Isavuconazonium sulfate 372 mg Q 8hour for 6 doses as loading dose, followed by 372 mg Q day as maintenance dose.

Trial Locations (1)

10021

Memorial Sloan Kettering Cancer Center, New York

All Listed Sponsors

collaborator

Astellas Pharma US, Inc.

INDUSTRY

lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT03149055 - Fungal Prophylaxis With Isavuconazole for Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant (HCT) | Biotech Hunter | Biotech Hunter